Altropane - Alseres Pharmaceuticals
Alternative Names: 123-I Altropane®; [123I]-E-IACFT Injection; [123I]NAV5001; Altropane; CFT; Iodine-123-E-IACFT Injection; NAV-5001; O 587Latest Information Update: 02 Oct 2021
At a glance
- Originator Harvard University
- Developer Alseres Pharmaceuticals
- Class Contrast media; Esters; Fluorobenzenes; Iodine radioisotopes; Radiopharmaceutical diagnostics; Small molecules; Tropanes
- Mechanism of Action Single-photon emission-computed tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Parkinsonian disorders
- Phase II Dementia
- No development reported Attention-deficit hyperactivity disorder
Most Recent Events
- 09 Jul 2019 Altropane is still in phase II trials for Dementia (Diagnosis) in USA (Alseres Pharmaceuticals pipeline, July 2019)
- 04 Jun 2015 NAV 2001 is still in phase III development for Parkinsonian disorders (Diagnosis) in USA
- 04 Jun 2015 Altropane® is available for licensing as of 04 Jun 2015. http://www.alseres.com/